The Lewis lab has had a long interest in the mechanisms of various aspects of diabetic dyslipidemia, including postprandial lipemia, HDL lowering and hypertriglyceridemia, as well as the metabolic effects of free fatty acids on insulin action and secretion. Dr. Lewis and Adeli made the important observation that the intestine overproduces lipoproteins in insulin resistant states, elucidating a number of regulatory mechanisms of intestinal lipid mobilization and lipoprotein secretion. In his current funded work, Dr. Lewis is determining, in integrative physiological studies in humans and animal models, the mechanisms of intestinal lipid mobilization and lipoprotein secretion. In addition, he is the Principal Investigator of Diabetes Action Canada, one of the chronic disease networks funded through the Strategy for Patient-Oriented Research (SPOR) Initiative, and undertakes translational research with active patient engagement.
Can J Diabetes. 2018 Sep 06;:
Diabetes Obes Metab. 2018 07;20(7):1751-1754
The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes.
Can J Cardiol. 2018 May;34(5):595-604
Trends Endocrinol Metab. 2018 Mar;29(3):151-163
Can J Diabetes. 2017 Dec;41(6):571-575
Curr Opin Lipidol. 2018 Feb;29(1):24-29
Arterioscler Thromb Vasc Biol. 2017 09;37(9):1776-1781
Ann Intern Med. 2017 Sep 05;167(5):360-361
Evaluation of the specific effects of intranasal glucagon on glucose production and lipid concentration in healthy men during a pancreatic clamp.
Diabetes Obes Metab. 2018 02;20(2):328-334
Diabetologia. 2017 10;60(10):2021-2032
Senior Scientist, Toronto General Hospital Research Institute (TGHRI)
Professor, Department of Medicine; and Department of Physiology
Director, Banting & Best Diabetes Centre
Sun Life Financial Chair in Diabetes
Drucker Family Chair in Diabetes Research